From Barchart: 2025-04-18 07:30:00

A pharmaceutical powerhouse is making strides with a strong pipeline, positioning itself as a dominant force in the future of medicine.



Read more at Barchart: Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?